Huasaiboman Medical Cell Biology
Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art cell therapy solutions.
Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art cell therapy solutions.
Huasaiboman Medical Cell Biology is a pioneering company dedicated to developing cutting-edge cell therapy solutions to revolutionize treatments for solid tumors and degenerative diseases. Founded in 2019, the company focuses on integrating clinical research with innovative cell therapy technologies. Specializing in tumor immunotherapy, Huasaiboman is committed to developing immune cell drug products targeting solid tumors, particularly tumor infiltrating lymphocyte (TIL) drugs. Additionally, the company focuses on stem cell therapy products for the treatment of degenerative diseases. Notably, collaborative efforts with various hospitals have led to the establishment of a research institute dedicated to clinical transformation, offering new hope for solid tumor patients. The company recently received a Series A investment at 28 December 2023, marking a significant milestone in its growth and development within the Biotechnology and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | - | 28 Dec 2023 | |
| Seed Round | Unknown | 1 |
|
23 Nov 2021 |
No recent news or press coverage available for Huasaiboman Medical Cell Biology.
We care about your data, and we'd love to use cookies make your experience better.